Potassium Chloride Tablet, Extended Release
Product Images NDC 59651-430

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Potassium Chloride (NDC 59651-430). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Package Label-principal Display Panel (10 mEq K (100 Tablets Bottle))

Package Label-principal Display Panel (10 mEq K (100 Tablets Bottle))
Each extended-release tablet contains 750 mg of USP potassium chloride equivalent to 10 mEq of potassium. It is distributed by Aurobindo Pharma USA, Inc. The usual dosage should be adjusted to the individual needs of each patient. The extended-release tablets should be stored at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The tablets come in a tight, light-resistant container as defined in the USP, and should be kept out of reach of children. The product is FDA-approved, and the sample preparation in the assay differs from the USP test. Full prescribing information is available in the accompanying package insert. Made in India.*
FDA Label Image

Package Label-principal Display Panel (15 mEq K (100 Tablets Bottle))

Package Label-principal Display Panel (15 mEq K (100 Tablets Bottle))
FDA Label Image

Package Label-principal Display Panel (20 mEq K (100 Tablets Bottle))

Package Label-principal Display Panel (20 mEq K (100 Tablets Bottle))
Each extended-release tablet contains 1500mg of Potassium chloride USP, equivalent to 20 mEg of potassium and is distributed by Aurobindo Pharma USA, Inc. The usual dosage should be adjusted according to individual patient needs, and full prescribing information can be found in the accompanying package insert. The tablets are made in India and must be kept out of reach of children. The FDA approved sample preparation for the assay differs from the USP test. The dotted lines in the overprinting zone/coding area should not be printed.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.